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  44 
ABSTRACT 45 
Background: Genome-wide association studies in asthma have repeatedly identified single 46 
nucleotide polymorphisms in the ORM (yeast)-like protein isoform 3 (ORMDL3) gene across 47 
different populations. Although the ORM-homologues in yeast are well-known inhibitors of 48 
sphingolipid (SL) synthesis, it is still unclear whether and how mammalian ORMDL3 49 
regulates SL metabolism and whether altered SL synthesis would be causally related to 50 
asthma risk.  51 
Objective: To examine the in vivo role of ORMDL3 in SL metabolism and allergic asthma 52 
Methods: Ormdl3-LacZ reporter mice, gene deficient Ormdl3-/- and overexpressing 53 
Ormdl3Tg/wt mice were exposed to physiologically relevant aeroallergens such as house dust 54 
mite or Alternaria alternata to induce experimental asthma. Mass spectrometry based 55 
sphingolipidomics was performed, and airway eosinophilia, Th2 cytokine production, Ig 56 
synthesis, airway remodeling and bronchial hyperreactivity measured.  57 
Results: HDM challenge significantly increased total sphingolipids in the lung of HDM-58 
sensitized mice compared to controls. In Ormdl3Tg/wt mice, the allergen-induced increase in 59 
lung ceramides was significantly reduced, whereas total sphingolipid levels were not affected. 60 
Conversely, in liver and serum, total sphingolipids including ceramides were increased in 61 
Ormdl3-/- mice, while they were lowered in Ormdl3Tg/wt mice. This difference was 62 
independent of allergen exposure. Despite these changes, all features of asthma were identical 63 
between wildtype, Ormdl3Tg/wt and Ormdl3-/- mice, across several models of experimental 64 
asthma.  65 
Conclusion: ORMDL3 regulates systemic ceramide levels, but genetically interfering with 66 
Ormdl3 expression does not result in altered experimental asthma.  67 
 68 
KEY MESSAGES 69 
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- Ormdl3 expression levels did not affect allergic asthma development driven by house dust 70 
mite or Alternaria alternata. 71 
- ORMDL3 negatively regulated ceramide levels, but this did not result in altered 72 
experimental asthma.  73 
 74 
CAPSULE SUMMARY 75 
ORMDL3 regulates systemic ceramide levels, but genetically interfering with Ormdl3 76 
expression does not result in altered experimental asthma.  77 
 78 
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α-SMA: alpha-smooth muscle actin 95 
SNPs: Single nucleotide polymorphisms 96 
SPT: Serine palmitoyl transferase  97 
 6 
INTRODUCTION 98 
Allergic asthma results from a complex gene-by-environment interaction and is currently still 99 
on the rise (1). Single nucleotide polymorphisms (SNPs) on chromosome 17q12-21 confer the 100 
most significant and replicated genetic susceptibility to childhood-onset asthma and 101 
rhinovirus-induced wheezing illness in childhood (2-8). Many of these SNPs fall within the 102 
promoter region of the ORM (yeast)-like protein isoform 3 (ORMDL3) gene and induce 103 
slightly elevated levels of ORMDL3, particularly in T lymphocytes and following stimulation 104 
of PBMCs with allergens (2,9-11). Ormdl3 mRNA is also upregulated in murine asthma 105 
models, driven by ovalbumin (OVA), house dust mite (HDM) or Alternaria alternata (12,13). 106 
However, studies addressing the functional role of ORMDL3 in asthma generated conflicting 107 
conclusions. Both transgenic overexpression as well as genetic deficiency of Ormdl3 can 108 
enhance key asthma features, whereas one study showed that Ormdl3 deficiency suppressed 109 
only bronchial hyperreactivity (BHR) (14-16). Given the multitude of genetic association 110 
studies in humans, the currently prevailing hypothesis is still that ORMDL3 overexpression 111 
has a causal role in asthma development or progression.  112 
The molecular mechanism by which ORMDL3 contributes to asthma is still a matter of 113 
intense debate (6,8). ORMDL3 is member of an evolutionary conserved family of 114 
endoplasmic reticulum (ER)-residing proteins, and has two paralogues in vertebrates, 115 
ORMDL1 and ORMDL2, that have not been associated with asthma (17). In yeast, the ORM 116 
homologues are described as regulators of de novo sphingolipid synthesis by controlling the 117 
activity of the rate limiting enzyme serine palmitoyl transferase (SPT) (18-23). In mammals 118 
however, ORMDLs lack the N-terminal phosphorylation site that is crucial for SPT regulation 119 
in yeast. Mammalian SPT activity seems to be affected only when all ORMDL paralogues are 120 
overexpressed or downregulated simultaneously (17,24-26), making it unlikely that SNPs in 121 
only ORMDL3 influence asthma by SPT inhibition. As an ER-resident protein, ORMDL3 has 122 
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also been described to affect calcium metabolism and the unfolded protein response, 123 
influencing cytokine secretion by structural or immune cells (6,12,27-29). However, most 124 
molecular studies on ORMDL3 were performed in vitro and have led to contradictory results 125 
due to the use of different cell lines and distinct approaches to measure total sphingolipid de 126 
novo synthesis and to control ORMDL3 expression. Furthermore, many studies were 127 
performed on epithelial cells, macrophages, mast cells and eosinophils (6,12,13,29-31), 128 
whereas it has been recently demonstrated that chr17q12-21 SNPs affect ORMDL3 expression 129 
most prominently in T-cells (9).  130 
Here, we addressed the role of ORMDL3 in SL metabolism and asthma in newly generated 131 
Ormdl3-LacZ reporter mice, full Ormdl3 KO mice (Ormdl3-/-), and mice overexpressing 132 
murine Ormdl3 from a Bacterial Artificial Chromosome (BAC)-transgene (Ormdl3Tg/wt). 133 
Using these unique gene-modified mice and their littermate controls, we found that ORMDL3 134 
expression influences ceramide levels in serum and liver and to a lesser extent in lung tissue. 135 
At the same time, interfering with Ormdl3 did not impact on key asthma parameters in 136 
various allergen driven asthma models. These data do not support the currently prevailing 137 






Ormdl3-LacZ reporter mice were generated by inserting a targeting construct of the European 144 
Conditional Mouse Mutagenesis consortium (project 72180) into the first intron of the 145 
Ormdl3 gene (Fig. 1A). This construct contains a sequence that consists of an En2 splice 146 
acceptor site, an internal ribosome entry site, a LacZ sequence, a polyA-tail, a loxP site, and a 147 
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neomycin coding sequence driven by a human β-actin promoter that is flanked by 2 Flp 148 
recombinase target (FRT) sites. ORMDL3 knockout (Ormdl3-/-) mice and ORMDL3 149 
transgenic (Ormdl3Tg/wt) mice were previously described (25). All mice were backcrossed for 150 
at least 10 crosses onto a C57BL/6 background. 1-DER mice express an MHC class II–151 
restricted TCR specific for Der p 1 on their CD4 T cells and were generated as previously 152 
described (32-34). Mice were bred under specific pathogen–free conditions at the animal 153 
house of the VIB/UGhent Center for Inflammation Research. Experiments were carried out 154 
using age- and gender-matched groups. All mice were used between 6-14 weeks of age. All 155 
animal procedures were approved by the Ethical Committee of Ghent University.  156 
 157 
Models of allergic asthma 158 
The HDM-induced asthma model was performed as described before (35). In brief, mice were 159 
sensitized intratracheally (i.t.) on day 0 with 1 μg HDM extract (Greer Laboratories, Lenoir, 160 
USA) or saline, followed by 10 μg intranasal (i.n.) challenges from day 6 to 10. On day 14, 161 
mice were euthanized by an overdose pentobarbital. In the chronic HDM-induced asthma 162 
model, mice were instilled i.n. with 10 ug HDM, or saline as a control, three times a week for 163 
5 weeks. Asthma features were determined 3 days after the last challenge. In the Alternaria-164 
induced asthma model, mice were instilled i.n. with 20ug Alternaria alternata (Greer 165 
Laboratories) three times a week for 3 weeks. All i.t. and i.n. treatments were given in 80 and 166 
40 ul PBS, respectively, and under light isoflurane anesthesia.  167 
Bronchoalveolar lavage (BAL) was performed using 3x1ml of EDTA-containing PBS (0,5 168 
mM). Blood was obtained from the iliac vein in non-coated Eppendorf tubes to prepare 169 
serum. Single cells suspensions from mediastinal lymph nodes were obtained by 170 
homogenizing the organ through a 100 um cell sieve. Cells were restimulated ex vivo with 15 171 
ug/ml HDM for 3 days and supernatants were collected for ELISA (Ready-set-go kits from 172 
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eBioscience). The left lung was fixed overnight in 4% paraformaldehyde and was used for 173 
histology. Right lung tissue was snap frozen in liquid nitrogen and kept at -80°C until used for 174 
RNA extraction.  175 
 176 
BHR determination 177 
Mice were anesthetized with urethane, paralyzed with D-tubocurarine, tracheostomized, and 178 
intubated with a 20-G catheter, followed by mechanical ventilation in a Flexivent apparatus 179 
(SCIREQ). Respiratory frequency was set at 150 breaths/min with a tidal volume (Vt) of 10 180 
ml/kg, and a positive-end expiratory pressure (PEEP) of 3 cm H2O was applied. Increasing 181 
concentrations of methacholine were nebulized (0–400 mg/ml) for 12 seconds and dynamic 182 
resistance, elastance and compliance were recorded by 12 repeat measurements during 2 183 
minutes per dose. Baseline resistance was restored in between the doses.  184 
 185 
Histology 186 
After overnight fixation in 4% paraformaldehyde solution, tissues were embedded in paraffin, 187 
cut into 5 um slices and stained with either Periodic Acid-Schiff (PAS) or processed for 188 
immunochemistry. Periodic Acid-Schiff staining was performed as described in Debeuf et al. 189 
(2016). To detect peribronchial α-smooth muscle actin (α-SMA), lung sections were 190 
overnight incubated with an anti-α-SMA primary antibody (A2547, Sigma-Aldrich). Species- 191 
and isotype-matched antibodies were used as negative controls. Immunoreactivity was 192 
detected by sequential incubations of lung sections with a biotinylated secondary Ab (E0433, 193 
Dako, Belgium), Vectastain Elite ABC kit (Vector Laboratories, Burlingame, California, 194 
USA), followed by 3,3-diaminobenzidine chromogen (Dako). Sections were mounted by use 195 




Individual sphingolipid species were quantified by a novel LC-MS method for a 199 
comprehensive analysis of typical and atypical sphingolipid species. A lipidomics profiling 200 
was done in 20 µL mouse serum or 20 µg of homogenate from lung tissue were extracted 201 
using the MMC protocol as described previously (36). d7-sphinganine, d7-sphingosine, Cer 202 
d18:0/12:0, Cer d18:1/12:0, SM d18:1/12:0, GluCer d18:1/18:0 and d7-S1P were used as 203 
internal standards. C18-column-based method for chromatographic separation and MS 204 
analysis was used, as described previously (36). 205 
 206 
Statistical analyses 207 
For all experiments, normality of each group was first checked by Shapiro-Wilk statistical 208 
test. If data sets were normally distributed, a One-Way ANOVA test was performed. In case 209 
of not normally distributed data, a Kruskal-Wallis test was done. All statistical tests were 210 
performed in GraphPad Prism. 211 
 212 
RESULTS 213 
Effect of allergen challenge on ORMDL3 expression in asthma 214 
One of the major drawbacks in the ORMDL3 field is the lack of specific antibodies, due to 215 
the large sequence homology with ORMDL1 and ORMDL2 (84% and 83%, respectively). 216 
Many investigators have therefore relied on ORMDL3 mRNA analysis of isolated tissues or 217 
cells, without confirming where exactly ORMDL3 is expressed. To be able to better address 218 
ORMDL3 expression, Ormdl3-LacZ reporter mice were generated by inserting a targeting 219 
construct into the first intron of Ormdl3 (Fig. 1A)(25). Although these mice still express some 220 
basal Ormdl3 (Fig. 1B), β-galactosidase activity can be used as readout for Ormdl3 promoter 221 
activation. We first compared ORMDL3 expression levels in different tissues in steady state 222 
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mice. Despite the fact that ORMDL3 is an asthma susceptibility gene, β-galactosidase 223 
expression was relatively low in lung tissue, especially compared to liver, and white and 224 
brown adipose tissues where ORMDL3 was abundantly present (Fig. 1C and Suppl. Fig. 1A). 225 
Similar results were obtained by RT-qPCR (Fig. 1D), consistent with RNA-seq data derived 226 
from the Genevestigator database (Suppl. Fig. 1B)(37). Previous studies suggested that 227 
epithelial cells would be the main cell type expressing ORMDL3 in the lung (14). However, 228 
in our hands, immunohistochemistry revealed diffuse and low β-galactosidase activity in 229 
subepithelial and vascular smooth muscle cells, epithelial cells and fibroblasts (Fig. 1E). On 230 
the contrary, high β-galactosidase activity was seen in white adipose tissue (Fig. 1E), 231 
consistent with mRNA expression data. 232 
To address whether ORMDL3 expression was induced by allergen challenge in vivo, we 233 
employed a previously established model in which inhaled HDM challenge of HDM-234 
sensitized mice leads to airway eosinophilia (Fig. 1F) (35). No increase in lung β-235 
galactosidase activity was seen in allergen-challenged mice compared to control PBS exposed 236 
mice (Fig. 1G and Suppl. Fig. 1C). These results showed that ORMDL3 expression in mouse 237 
lungs is low and did also not increase after allergen challenge using sensitized mice. 238 
 239 
Characterization of Ormdl3Tg/wt and Ormdl3-/- mice 240 
To assess the effects of altered ORMDL3 expression levels in vivo, we have recently 241 
generated Ormdl3-overexpressing mice (Ormdl3Tg/wt) and gene deficient Ormdl3-/- mice (25). 242 
Before we used these mice in asthma experiments, we wanted to address if immune cell 243 
development was affected by a systemic change in Ormdl3 expression. Mice from both strains 244 
were healthy and did not develop a spontaneous phenotype, even with ageing (data not 245 
shown). We stained cells with a broad panel of antibodies recognizing various lymphocytes 246 
and myeloid cells and used the FlowSOM automatic gating and visualization tool to assess the 247 
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immune cell landscape of Ormdl3Tg/wt and Ormdl3-/- mice in the most unbiased manner (38-248 
40). Although there was a trend to an increased number of splenic cells in Ormdl3Tg/wt mice 249 
(Fig. 2A/B), none of the well known or less defined immune cell clusters were significantly 250 
altered compared with littermate controls (Fig. 2C/D). Likewise, FlowSOM trees represented 251 
a similar immune landscape between Ormdl3-/- mice and littermate controls (Fig. 2E-H). 252 
These data suggest that genetic alteration of ORMDL3 does not affect the immunome in a 253 
major manner. 254 
 255 
Effect of altered ORMDL3 expression on sphingolipid concentration 256 
In yeast, it has been conclusively demonstrated that ORM-proteins regulate de novo 257 
sphingolipid synthesis via controlling SPT activity. Therefore a dysregulation of sphingolipid 258 
de novo synthesis was proposed as a pathophysiological mechanism by which ORMDL3 259 
promotes asthma (for a schematic overview of SL de novo synthesis, see Suppl. Fig. 2A) 260 
(8,18-23,41). We therefore assessed whether ORMDL3 affects sphingolipid metabolism in 261 
the context of allergic asthma by using our transgenic mice. Since there are three ORM 262 
paralogues expressed in mice, it was also important to assess if deficiency or overexpression 263 
of Ormdl3 causes a compensatory change in Ormdl1 or Ormdl2 expression. For lung tissue, 264 
Ormdl3 transcript levels were 6 fold increased in Ormdl3Tg/wt and expression levels were 265 
comparable for non-asthmatic (PBS/HDM group) and asthmatic (HDM/HDM group) 266 
conditions. A compensatory change in Ormdl1 or Ormdl2 expression was not observed (Fig. 267 
3A). In Ormdl3-/- mice, transcript levels of Ormdl3 were absent, without a sign of 268 
compensatory upregulation of Ormdl1 or Ormdl2 (Fig. 3B). Again, we did not observe any 269 
induction of Ormdl3 mRNA upon asthmatic challenge (Fig. 3A-B). 270 
Next, we investigated how asthma and ORMDL3 expression influenced the sphingolipid 271 
profile in various organs. We observed a mixed picture, depending on the analyzed tissue. In 272 
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lung, total sphingolipid levels were increased in asthmatic mice compared to non-asthmatic 273 
mice, confirming previous observations (13,42), but this increase was clearly independent of 274 
Ormdl3 (Fig. 3C/D). In line with this, full sphingolipidomics analysis revealed an increase of 275 
ceramides in lungs of asthmatic mice (Fig. 3E/F), which appeared not affected by the absence 276 
of ORMDL3 (Fig. 3F). However, upon overexpression of ORMDL3, ceramide levels in the 277 
lung were slightly decreased, consistent with a role for ORMLD3 in blocking ceramide 278 
synthesis (13,43)(Fig. 3E). This was much more pronounced in the serum (Fig. 3G/H) and 279 
several other tissues, such as liver and fat in which ORMDL3 is higher expressed (Fig. 1C, 280 
Fig. 3G/H and Suppl. Fig. 2). These effects were not limited to ceramides but could also be 281 
observed for other sphingolipid species. For instance, sphingosine-1-phosphate (S1P) and 282 
sphinganine-1-phosphate (SA1P) were upregulated in serum from Ormdl3-/- mice and reduced 283 
in Ormdl3Tg/wt mice (Fig. 3C/D). A similar pattern was observed for hexosylceramides and 284 
sphingomyelins (Suppl. Fig. 2E-G). In summary, sphingolipid homeostasis seems to be 285 
mostly influenced in those tissues where ORMDL3 is abundantly expressed. For lung, we did 286 
not see a major influence of ORMDL3 expression on the asthma-induced change in the SL 287 
profile.  288 
 289 
Genetic alteration of ORMDL3 expression levels does not affect key asthma parameters 290 
Having found that genetic interference with the expression levels of ORMDL3 led to 291 
alterations in ceramide levels, we next addressed if key asthma parameters would be altered in 292 
Ormdl3Tg/wt or Ormdl3-/- mice, and experiments were each time compared to proper littermate 293 
wildtype controls. In HDM-sensitized, but not mock-sensitized, Ormdl3wt/wt mice, there was 294 
eosinophil, T cell and B cell infiltration in bronchoalveolar lavage (BAL) fluid, IL-5 and IL-295 
13 cytokine production in the MLN, and HDM-specific IgE production in the serum, and 296 
bronchial hyperreactivity in response to increasing doses of metacholine (Fig. 4A-D and 297 
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Suppl. Fig. 3A/B). Strikingly, none of these key HDM-induced asthma parameters were 298 
altered in Ormdl3Tg/wt mice. A previous study suggested the involvement of ORMDL3 in 299 
airway remodeling, characterized by goblet cell metaplasia (GCM) and hypertrophia of α-300 
smooth muscle actin (α-SMA) expressing myofibroblasts (Miller et al. 2014). In Ormdl3wt/wt 301 
mice, HDM challenge of sensitized mice led to an increase in PAS-positive GCM, and of α-302 
SMA staining around the airways compared to non-sensitized mice (Fig. 4E-F), but again 303 
these features were equally induced in Ormdl3Tg/wt mice. Even in a more chronic 5 week 304 
model of HDM exposure, overexpression of ORMDL3 did not significantly influence cardinal 305 
features of asthma (Suppl. Fig. 3C-G).  306 
Recently, it has been shown that T-cells are the most prominent immune cells affected by 307 
chr17q21 SNPs (9). Therefore, we wondered whether T-cell function would be intrinsically 308 
affected by ORMDL3 overexpression. Although there were no obvious differences in the 309 
outcome of the asthma experiments, it was still possible that T-cell function was slightly 310 
affected, but that this only became apparent during competition experiments. Therefore, we 311 
crossed Ormdl3Tg/wt with 1-DER mice, which contain T-cells that specifically react to the Der 312 
p 1 peptide of HDM (32). Ormdl3wt/wt and Ormdl3Tg/wt 1-DER T cells were fluorescently 313 
labelled and transferred into acceptor mice (Suppl. Fig. 4A), which were subsequently 314 
exposed to HDM. Similar proportions of Ormdl3wt/wt and Ormdl3Tg/wt 1-DER T cells were 315 
divided three days after transfer and numbers were equally high (Suppl. Fig. 4B-C). Thus, in 316 
line with previous results, ORMDL3 did not affect HDM-specific proliferation by T cells 317 
intrinsically.  318 
To exclude allergen-dependent effects, Ormdl3Tg/wt mice were also exposed to a model driven 319 
by the fungal extract Alternaria alternata. Mice were administered 20 Pg Alternaria (ALT) or 320 
PBS three times a week, for 3 weeks (Suppl. Fig. 5A). ALT-treated mice had elevated 321 
expression levels of Ormdl3 mRNA, confirming earlier findings (Miller et al. 2012) (Suppl. 322 
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Fig. 5B), however this could not be confirmed on protein level with Ormdl3-LacZ reporter 323 
mice (Suppl. Fig. 5C). In ALT exposed mice, there was a marked influx of eosinophils in the 324 
BAL fluid, an increase in ALT-specific IgE in the serum, Th2 cytokine production in the 325 
MLN, and development of BHR to methacholine compared with PBS exposed mice, but none 326 
of these features were altered in Ormdl3Tg/wt mice (Fig. 4G-I and Suppl. Fig. 5D-F).  327 
It is most likely that the ORMDL3 SNP at 17q12-21 that confers asthma risk leads to 328 
overexpression of ORMDL3, as has been demonstrated in T-cells (9). Since our transgenic 329 
mice overexpressing ORMDL3 did not have altered features of asthma, we also decided to 330 
perform all key asthma readouts in Ormdl3-/- mice in comparison with Ormdl3+/+ littermates, 331 
again sensitizing mice to either HDM or ALT. Whereas all key features of allergic asthma 332 
like eosinophilia, Th2 cytokine production, HDM-specific serum IgE, BHR to methacholine, 333 
airway remodeling were induced by allergen challenge in Ormdl3+/+ mice, none of these 334 
features were altered in Ormdl3-/- mice (Fig. 5A-F and Suppl. Fig. 6A). There was a small 335 
trend towards enhanced IL-17 production by allergen restimulated MLN T cells, but this was 336 
not accompanied by airway neutrophilia (Suppl. Fig. 6B). Similar conclusions were reached 337 
in the ALT model (Fig. 5G-I and Suppl. Fig. 6C-F). Therefore, neither ORMDL3 338 
overexpression nor deletion affected key asthma parameters in various acute and chronic 339 





During the last decade, genome-wide association studies have repeatedly and convincingly 344 
demonstrated that SNPs in the chr17q12-21 locus are associated with the early life onset of 345 
allergic asthma (2,3). Genotypes in the core region defined by the first genome-wide 346 
association study correlate with expression of 2 genes, ORMDL3 and gasdermin B (GSDMB), 347 
making these prime candidate asthma genes, although recent studies have implicated 348 
gasdermin A (GSDMA) distal to and post-GPI attachment to proteins 3 (PGAP3) proximal to 349 
the core region as independent loci (8). There is much speculation on how ORMDL3 could 350 
regulate asthma. In yeast, ORM proteins control sphingolipid levels by regulating the enzyme 351 
SPT, the rate-limiting enzyme of de novo sphingolipid synthesis (18). A mouse study 352 
subsequently showed that interfering with SPT using the inhibitor myriocin reduced de novo 353 
sphingolipid synthesis and increased bronchial hyperreactivity (44). This led some to 354 
conclude that ORMDL3 controls asthma via altered sphingolipid metabolism (41,45). 355 
However, despite extensive efforts, the molecular role of ORMDL3 in allergic asthma has not 356 
been unraveled yet.  357 
Although the studies addressing the effect of inhibition of de novo SL synthesis using 358 
myriocin or genetic deficiency of SPT have yielded consistent results (13,24,26,44,46-50), the 359 
mouse studies investigating the role of ORMDL3 in asthma have been harder to reconcile. 360 
Miller et al. (2014) reported that C57BL/6 mice expressing high levels of human ORMDL3 361 
developed stronger inflammation and BHR compared to wildtype mice in a mouse model 362 
driven by intraperitoneal immunization by OVA in alum followed by a series of OVA 363 
inhalation challenges (14). However, the same group also reported that BHR (but not 364 
inflammation) was increased in C57BL/6 mice lacking ORMDL3 specifically in epithelial 365 
cells (16), which makes the results hard to interpret. In contrary, Loser et al. (2016) reported 366 
that full Ormdl3 gene deficient C57BL/6 mice were protected from developing BHR to 367 
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Alternaria alternata, whereas inflammation was only slightly affected. From these conflicting 368 
studies, the conclusion would be that the role of ORMDL3 in experimental asthma is highly 369 
contextual, and might be explained by subtle differences in animal models used by different 370 
investigators, and whether the model employed overexpression of (human) ORMDL3 or 371 
genetic deficiency of endogenous mouse Ormdl3. To address this controversy regarding the 372 
models used, we applied multiple models (acute versus chronic) and allergens (HDM, 373 
Alternaria, and OVA, not shown) in newly generated Ormdl3 BAC transgenic and Ormdl3-/- 374 
mice. We observed no differences in the severity of all key asthma parameters when Ormdl3 375 
was either overexpressed or deleted from the mouse genome. At present, we can only 376 
speculate about the differences between our negative results and the positive results reported 377 
by others. One major difference is that others studying overexpression have employed the 378 
human ORMDL3 gene using a plasmid expression system or adenoviral overexpression of 379 
murine Ormdl3 in vivo, which could have led to unphysiological levels of overexpression, or 380 
overexpression in cell types that normally do not express ORMDL3. In addition, the reported 381 
differences in ORMDL3 expression based on the SNP genotype, is minor and significantly 382 
smaller as it was reported for the transgenic mouse models. We have used a BAC transgenic 383 
construct in which overexpression of Ormdl3 is still driven by the endogenous Ormdl3 384 
promotor. Modeling asthma in the mouse is difficult. It is possible that other environmental 385 
triggers that often occur together with allergen exposure are necessary to unravel the link 386 
between ORMDL3 and asthma, such as respiratory viruses or cigarette smoke. In fact, a 387 
limitation of this study is the lack of a viral infection model, as recent epidemiological studies 388 
suggest that SNPs in the chr17q12-21 locus combined with severe respiratory virus infections 389 
do have a driving role in causing childhood-onset asthma (7,51,52). Interestingly, the same 390 
SNPs also lead to protection from asthma upon microbial exposure (51), suggesting that this 391 
locus is very environment-dependent and might be regulated by epigenetic modifications (53). 392 
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None of the studies addressing the relationship between ORMDL3 and asthma have so far 393 
studied experimental respiratory viral infections. Efforts are underway in our laboratory 394 
addressing the role of ORMDL3 in susceptibility to respiratory mouse pneumovirus infection 395 
and subsequent asthma development. 396 
 397 
ORM-homologues in yeast are well-known inhibitors of de novo sphingolipid synthesis, 398 
whereas the role for the mammalian ORMDLs is still a matter of debate. We therefore 399 
examined sphingolipid synthesis by two approaches. First, we analyzed the total SL levels by 400 
quantifying the total C18-sphingoid base profile after chemical hydrolysis. If SPT-activity 401 
would be inhibited by ORMDL3, total sphingoid bases would be reduced in Ormdl3Tg/wt mice. 402 
However, neither in lungs of Ormdl3Tg/wt nor in Ormdl3-/- mice, a significant change in total 403 
sphingoid base levels could be detected. That corresponds to earlier reports that SPT-activity 404 
is not affected by changing ORMDL3 expression levels (25). Next, we performed 405 
sphingolipidomic analysis to quantify individual sphingolipid species, including ceramides, 406 
sphingomyelins, hexosyl ceramides and phosphorylated sphingoid bases (S1P, SA1P). In 407 
particular S1P has been extensively described to be involved in allergic asthma (54-58). Our 408 
results demonstrate an increase in serum S1P in Ormdl3-/- mice (Fig. 3D), which has also been 409 
seen in mice lacking ORMDL3 specifically in epithelial cells (16). Furthermore, Ormdl3Tg/wt 410 
mice had reduced levels of S1P (Fig. 3C), which is consistent with previous reports (43). 411 
However, the ORMDL3-dependent regulation of S1P did not result in an altered asthma 412 
phenotype. 413 
Earlier reports have shown that ceramides are elevated in murine allergic asthma models and 414 
asthmatic patients and that inhibition of ceramide synthesis mitigates the allergic response 415 
(13,42). This was confirmed in our HDM model, which showed a significant increase in lung 416 
ceramides for asthmatic mice compared to non-asthmatic mice. This asthma dependent 417 
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increase in Cer was not influenced in Ormdl3-/- mice. On the other hand, it appeared to be 418 
hampered in Ormdl3Tg/wt mice. Of interest, serum ceramides were decreased in Ormdl3Tg/wt 419 
mice and conversely, were increased in Ormdl3-/- mice. Similar changes were seen in liver but 420 
not in BAT or WAT, which also express significant levels of ORMDL3 natively (Fig. 1C). A 421 
decrease in long-chain ceramides (C:24) has also been observed in mice overexpressing 422 
human ORMDL3 (43). Furthermore, Oyeniran et al. (2015) reported that all ceramide species 423 
were reduced upon overexpression of ORMDL3, provided that the degree of overexpression 424 
is moderate, which is the case in our Ormdl3Tg/wt mice. However, although serum (and lung) 425 
ceramide levels did change upon changing ORMDL3 expression levels, the allergic response 426 
was not affected, suggesting that the association of ORMDL3 with asthma would be hard to 427 
explain through alterations in ceramide levels.  428 
In tissues where native ORMDL3 expression was the highest — based on the Ormdl3-LacZ 429 
reporter mouse — the effects on sphingolipid homeostasis were also the most pronounced. 430 
This may explain the moderate effects observed in lung. However, it is still unclear at which 431 
step ORMDL3 interferes in the sphingolipid synthesis pathway. In line with our previous data 432 
(25), we did not find a consistent change in total sphingolipid levels, which makes a direct 433 
effect of ORMDL3 on SPT activity questionable. Still, especially in liver but also other 434 
tissues, levels of several sphingolipid species were altered in mice with deregulated Ormdl3. 435 
Interestingly, the largest change was seen for serum SM, which is primarily formed in the 436 
liver and then secreted into blood in the form of lipoproteins. Among the different SL classes, 437 
we observed the most pronounced changes for Cer and SM whereas HexCer level were not 438 
much altered. This shows that mammalian ORMDL3 is somehow involved in the homeostasis 439 
of sphingolipids, but likely at a level downstream of SPT. 440 
As an ER-residing protein, in vitro studies also reported a role for ORMDL3 in calcium 441 
homeostasis and the unfolded protein response (12,27,28), although there are also reports 442 
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demonstrating no role for ORMDL3 in the UPR (29). We measured UPR target gene 443 
expression in different tissues from Ormdl3-/- and Ormdl3Tg/wt mice, but could not find any 444 
differences compared to wildtype mice (data not shown), suggesting that the UPR was not 445 
affected upon changing ORMDL3 expression levels in vivo. It should be noted that a dramatic 446 
overexpression of ER proteins will affect ER homeostasis anyway, so the positive findings 447 
described in vitro may not be directly linked to ORMDL3.  448 
Thus, in this study we found no causal relationship between ORMDL3 expression levels and 449 
severity of key asthma features in a HDM or Alternaria-driven allergic asthma model, despite 450 
clear alterations in sphingolipid levels in mice overexpressing or lacking ORMDL3. We 451 
therefore do not support the hypothesis that ORMDL3 controls asthma by altering 452 
sphingolipid metabolism. More research is needed on the causal relationship between 453 
respiratory virus infection, SNPs at 17q21, ORMDL3 levels and asthma risk, before we can 454 
definitively exclude a major role for ORMDL3 in asthma. 455 
 456 
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FIGURE LEGENDS 668 
Figure 1: Ormdl3-LacZ reportermice as a useful tool to study ORMDL3 expression 669 
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A) Ormdl3-LacZ reportermice (Ormdl3LacZ/LacZ) were generated by inserting a targeting 670 
construct of the EUCOMM consortium into the first intron of Ormdl3. Exon 2, exon 3 and 671 
part of exon 4 are flanked by two loxP sites, which enable the generation of conditional 672 
knockout mice upon crossing with mice expressing Cre-recombinase.  673 
B) Ormdl3 mRNA expression levels in lungs from Ormdl3+/+, Ormdl3LacZ/LacZ and Ormdl3-/- 674 
mice. Expression values are shown relative to means of the wildtype group. Data were pooled 675 
from 2 experiments (n=7,6,4; means +/- SEM).   676 
C) Western blot showing β-galactosidase expression in liver, lung, brown adipose tissue 677 
(BAT) and white adipose tissue (WAT) in three individual Ormdl3-LacZ reportermice. β-678 
tubulin was used as a loading control.  679 
D) Ormdl3 transcript levels in lung, BAT, WAT and liver in wildtype mice. Expression 680 
values are shown relative to means of lung samples (means +/- SEM).   681 
E) Immunohistochemistry analysis of β-galactosidase expression (blue) on lung OCT-inflated 682 
cryosections and WAT of Ormdl3-LacZ reportermice. Periodic-acid Schiff staining was used 683 
as counterstaining. A = airway; Bv = blood vessel; Alv = alveoli. 684 
F) Scheme representing the acute house dust mite (HDM)-dependent asthma model.  685 
G) Western blot showing β-galactosidase expression in lung tissue from mock- and HDM-686 
challenged Ormdl3-LacZ reportermice. 687 
 688 
Figure 2: Unbiased analysis of the immune landscape of Ormdl3Tg/wt and Ormdl3-/- mice 689 
A) Splenic cell number from 6w old Ormdl3wt/wt and Ormdl3Tg/wt mice (n=5,5). 690 
B/C) Numbers (B) and percentages (C) of different immune cell types in spleens from 691 
Ormdl3wt/wt and Ormdl3Tg/wt mice (n=5,5). 692 
D) FlowSOM trees representing the splenic immune landscape in Ormdl3wt/wt and Ormdl3Tg/wt 693 
mice. 694 
E) Splenic cell number from 6w old Ormdl3+/+ and Ormdl3-/- mice (n=5,5). 695 
F/G) Numbers (F) and percentages (G) of different immune cell types in spleens from 696 
Ormdl3+/+ and Ormdl3-/- mice (n=5,5). 697 
H) FlowSOM trees representing the splenic immune landscape in Ormdl3+/+ and Ormdl3-/- 698 
mice. 699 
Data information: All data were analysed with a Shapiro-Wilk normality test to assess 700 
whether the data was normally distributed. Parametric data were analysed with a t-test, 701 
whereas non-parametric data were analysed with a Mann-Whitney test. Data are shown as 702 
means +/- SEM. *p<0.05. 703 
 704 
Figure 3: Effect of altered ORMDL3 expression on sphingolipid concentration 705 
A/B) Ormdl mRNA expression levels in lung tissue from Ormdl3wt/wt and Ormdl3Tg/wt mice 706 
(A) or Ormdl3+/+ and Ormdl3-/- mice (B) sensitized with saline (PBS) or house dust mite 707 
(HDM) and challenged with HDM. Expression values are shown relative to means of the 708 
mock-sensitized wildtype group (A: n=5,10,7,15; B: 8,8,3,6). 709 
C/E) C18-sphingoid base levels in lung tissue from (non)-asthmatic Ormdl3wt/wt and 710 
Ormdl3Tg/wt mice (C) or Ormdl3+/+ and Ormdl3-/- mice (E). Total SLs were extracted, and 711 
sphingosine (C18SO, grey) and sphinganine (C18SA, black) levels were analyzed after acid-712 
base hydrolysis by liquid chromatography-mass spectrometry (C: n=8,13,6,10; E: n=5,5,7,7). 713 
D/F) Sphingosine-1-phosphate (S1P, grey) and sphinganine-1-phosphate (SA1P, black) levels 714 
in serum from (non)-asthmatic Ormdl3wt/wt and Ormdl3Tg/wt mice (D) or Ormdl3+/+ and 715 
Ormdl3-/- mice (F) (D: n=8,13,6,10; F: n=7,7,6,7). 716 
G-J) Ceramide levels in lung tissue (G/H) or serum (I/J) from (non)-asthmatic Ormdl3wt/wt and 717 
Ormdl3Tg/wt mice (G/I) or Ormdl3+/+ and Ormdl3-/- mice (H/J) (G/I: n=8,13,6,10; H: n=5,5,7,7; 718 
J:7,7,6,7). 719 
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C/D/G/I) Data were pooled from 3 independent experiments. 720 
Data information: All data were analysed with a Shapiro-Wilk normality test to assess 721 
whether the data was normally distributed. Parametric data were analysed with an ordinary 722 
one-way ANOVA test with multiple comparison correction. Non-parametric data were 723 
analysed with an unpaired Kruskal-Wallis test with multiple correction. Data are shown as 724 
means +/- SEM. *p<0.05; **p<0.01, ***p<0.001, ****<0.0001. 725 
 726 
Figure 4: ORMDL3 overexpression does not affect allergic asthma driven by HDM or 727 
Alternaria alternata 728 
A) Eosinophil number in BAL fluid from (non)-asthmatic Ormdl3wt/wt and Ormdl3Tg/wt mice 729 
(n=5,11,7,14). 730 
B) Protein levels of IL-5 and IL-13 secreted by MLN cells during restimulation with HDM 731 
(n=5,11,7,14). 732 
C) Serum HDM-specific IgE levels (OD value) (n=4,11,6,13).  733 
A-C) Data were pooled from 2 independent experiments. 734 
D) Bronchial hyperreactivity upon exposure to increasing doses of methacholine (Mch) as 735 
measured with flexiVent (n=4,4,6,8). 736 
E) Representative images of lung sections stained with either Periodic Acid-Schiff (PAS) or 737 
anti-α-smooth muscle actin (α-SMA) antibody. Scale bar = 100 um.   738 
F) Quantification of PAS+ area and peribronchial α-SMA in lung tissue. Data were pooled 739 
from 3 independent experiments (n=1,15,1,9). 740 
G) Eosinophil number in BAL fluid upon exposure to PBS or Alternaria (n=1,8,1,9).  741 
H) Serum Alternaria-specific IgE levels (OD value) (n=1,6,1,4).  742 
I) Bronchial hyperreactivity upon exposure to increasing doses of methacholine (Mch) as 743 
measured with flexiVent (SCIREQ) (n=1,7,1,4). 744 
Data information: All data were analysed with a Shapiro-Wilk normality test to assess 745 
whether the data was normally distributed. Parametric data were analysed with an ordinary 746 
one-way ANOVA test with multiple comparison correction. Non-parametric data were 747 
analysed with an unpaired Kruskal-Wallis test with multiple correction. For F-I, a Mann-748 
Whitney statistical test was performed between the HDM-sensitized groups. Data are shown 749 
as means +/- SEM. *p<0.05; **p<0.01, ***p<0.001.  750 
 751 
Figure 5: Loss of Ormdl3 expression does not affect allergic asthma driven by HDM or 752 
Alternaria alternata 753 
A) Number of eosinophils in BAL fluid from (non)-asthmatic Ormdl3+/+ and Ormdl3-/- mice 754 
(n=10,11,7,14).  755 
B) Protein levels of IL-5 and IL-13 secreted by MLN cells during restimulation with HDM 756 
(n=10,11,7,14).  757 
C) Serum HDM-specific IgG1, HDM-IgE and total IgE levels (OD value) (n=8,12,12,16).  758 
A-C) Data were pooled from 2 experiments. 759 
D) Bronchial hyperreactivity upon exposure to increasing doses of methacholine (Mch) as 760 
measured with flexiVent (n=4,4,6,6). 761 
E) Representative images of lung sections stained with either Periodic Acid-Schiff (PAS) or 762 
anti-α-SMA antibody. Scale bar = 100um.   763 
F) Quantification of PAS+ area (n=5,7,7,8) and peribronchial α-SMA (n=5,6,7,8) in lung 764 
tissue.  765 
G) Number of eosinophils in BAL fluid from Ormdl3+/+ and Ormdl3-/- mice exposed to PBS or 766 
Alternaria (n=2,10,2,9).  767 
H) Serum Alternaria-specific IgE levels (OD value) (n=4,6,4,6).  768 
I) Bronchial hyperreactivity upon exposure to increasing doses of methacholine (Mch) as 769 
 28 
measured with flexiVent (SCIREQ) (n=4,6,4,6). 770 
Data information: All data were analysed with a Shapiro-Wilk normality test to assess 771 
whether the data was normally distributed. Parametric data were analysed with an ordinary 772 
one-way ANOVA test with multiple comparison correction. Non-parametric data were 773 
analysed with an unpaired Kruskal-Wallis test with multiple correction. Data are shown as 774 
means +/- SEM. *p<0.05; **p<0.01, ***p<0.001, ****<0.0001. 775 
 1 
SUPPLEMENTARY METHODS 1 
 2 
Immunoglobulin production 3 
Mice were bled under terminal anesthesia, and serum was collected by centrifugal phase 4 
separation to determine IgE and IgG1 levels by ELISA (BD Biosciences). For HDM-specific 5 
IgG1, ELISA plates were coated with 100 ug/ml HDM (Greer Laboratories). For HDM-6 
specific IgE, ELISA plates were coated with an anti-IgE capture antibody (BD Biosciences) 7 
and the detection was performed with biotin-labeled HDM (100 ug/ml), diluted in PBS + 10% 8 
FCS.  9 
 10 
Flow cytometry 11 
Bronchoalveolar lumen fluid was obtained by flushing the lungs with EDTA-containing PBS 12 
(0,5 mM). Cell suspensions were stained with antibody cocktails in PBS for 30 min at 4°C, 13 
and subsequently washed in PBS before readout. Unspecific antibody binding was prevented 14 
by adding 2.4G2 (antibody to the Fcc receptor II/III) during the staining. A fixed amount of 15 
counting beads (123count ebeads, Thermo Fisher Scientific) was added to determine absolute 16 
cell numbers. Dead cells were excluded using the Fixable Viability Dye eFluor506 17 
(eBioscience). Data acquisition was performed on a 4-laser Fortessa (BD Biosciences) and 18 
data were analyzed using FlowJo (Tree Star, Inc). Eosinophils were gated as CD11c- CD3/19- 19 
Ly6G- CD11bhi, SiglecFhi, SSC-Ahi; T-cells as CD11c- CD3/19+ MHCII- and B-cells as 20 
CD11c- CD3/19+ MHCII+. 21 
 22 
FlowSOM 23 
The automated analysis is done by the FlowSOM algorithm (1,2). FlowSOM uses a self-24 
organizing map to cluster cells in different nodes based on the expression of the distinct 25 
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markers used in a given flow cytometry dataset and subsequently structures the nodes in a 26 
minimal spanning tree. We first concatenated live cells and used FlowSOM to generate a 27 
single FlowSOM tree. 28 
 29 
Image quantification 30 
To perform objective image quantification, a Fiji-based software script was applied to 31 
quantify PAS+ cells and α-SMA in the lung. To detect the whole tissue, RGB images were 32 
converted to 8-bit images and binary masks were created by the ‘auto threshold mean’ method 33 
(3). Filtering by size allowed to distinguish lung tissue from air space in the lung. Then, 34 
depending on the staining method, color deconvolution was applied as described in Ruifrok et 35 
al. (2001) (4). Positively stained cells were detected by the Renyi’s Entropy thresholding 36 
method (5) and binary particle analysis was performed to filter particles by size. The 37 
positively stained area was then normalized to the total area of the lung.  38 
 39 
Immunoblotting 40 
Lung tissue was snap-frozen in liquid nitrogen during dissection. Lungs were homogenized 41 
with TissueLyser II (Qiagen) in 400μl E1A buffer (1% NP40, 20 mM HEPES, pH 7.9, 250 42 
mM NaCl, 1 mM EDTA) complemented with cOmplete-ULTRA (Roche) protease inhibitors. 43 
Prior to SDS–PAGE, samples were spun at 12,000g to remove insoluble material. Protein 44 
concentration was determined by Bradford assay. Samples were boiled for 5 min at 95°C 45 
before loading. After wet transfer to polyvinyldifluoride membrane (Immobilon; Millipore), 46 
proteins were analyzed by immunoblotting and visualized by chemiluminescence (NEL 47 
104001EA; Perkin Elmer). Primary antibodies used recognize beta-galactosidase (ab4761, 48 
Abcam, 1/1000) and beta-tubulin (ab21058, Abcam, 1/5000). Goat anti-rabbit-HRP (P0448, 49 
Dako, 1/2000) was used as secondary antibody. 50 
 3 
1-DER T cell adoptive transfer 51 
1-DER T cells were isolated out of spleen and lymph nodes from Ormdl3wt/wt and Ormdl3Tg/wt 52 
1-DER mice. T cells were purified by making use of the MagniSort Mouse CD4 T cell 53 
Enrichment Kit (ThermoFisher) and were labeled with Cell Trace Violet (Invitrogen) during 54 
10 minutes at 37°C. 1x106 1-DER cells of each genotype were intravenously injected into 55 
CD45.1 B6 acceptor mice, followed by intratracheal installation of 10 ug HDM 2 hours after 56 
IV injection. Acceptor mice were sacrificed 3 days later and mLN, lung and spleen were 57 
dissected for analysis.  58 
  59 
Quantitative real time-PCR 60 
Total RNA was isolated from mouse lung tissues by using the TriPure Isolation Reagent 61 
(Roche, Mannheim, Germany) and isolated according to the manufacturer’s instructions. 1 ug 62 
RNA was converted to cDNA by an iScript advanced reverse transcriptase (Bio-Rad) 63 
according to manufacturer’s instructions. The target cDNA was amplified by 30 cycles of 64 
PCR by using LightCycler® 480 Probes Master Mix (Roche) and the following primers: 65 
Ormdl3: (forward) CCCTCACCAACCTTATCCAC, (reverse) 66 
GGACCCCGTAGTCCATCTG; and universal probe #109 (Universal Probe Library, Roche, 67 
Indianapolis, IN, USA). Expression levels were calculated by using qBase+ software 68 
(Biogazelle, Ghent, Belgium) and normalized to the two most stable reference genes among 69 
Hmbs, Sdha, Hprt, Rpl13a and Gapdh. To amplify reference genes, SensiFAST SYBR® No-70 
ROX Kit (GC Biotech) was used and primers were as follows: Hmbs: (forward) 71 
GAAACTCTGCTTCGCTGCATT, (reverse) TGCCCATCTTTCATCACTGTATG; Sdha: 72 
(forward) TTTCAGAGACGGCCATGATCT, (reverse) TGGGAATCCCACCCATGTT. 73 
Hprt: (forward) TGAAGAGCTACTGTAATGATCAGTCAAC, (reverse) 74 
AGCAAGCTTGCAACCTTAACCA; Rpl13a (forward) CCTGCTGCTCTCAAGGTTGTT, 75 
 4 
(reverse) TGGTTGTCACTGCCTGGTACTT and Gapdh: (forward) 76 
GCATGGCCTTCCGTGTTC, (reverse) TGTCATCATACTTGGCAGGTTTCT. 77 
 78 
Tissue homogenization preceding lipid extraction 79 
Tissues were homogenized in lysis buffer [25 mM HEPES pH 8, 0.2% Triton X-100 80 
(vol/vol)] using a Precellys 24 tissue homogenizer (Bertin Technologies, Montigny-le-81 
Bretonneux, France). A volume that contained 100 mg protein (as determined by the Bradford 82 
assay) was filled up to 100 ml with saline for SL extraction.  83 
 84 
Lipid extraction and sphingoid base analysis  85 
Methanol (500 ml; Honeywell, Morris Plains, NJ, USA) containing 200 pmol internal 86 
standards (d7-sphinganine and d7-sphingosine; Avanti Polar Lipids, Alabaster, AL, USA) 87 
were added to tissue homogenate containing 100 mg protein, or 100 μl serum, followed by 88 
gentle rotation at 1400 rpm and 37°C for 1 h (Thermomixer comfort; Eppendorf, Hamburg, 89 
Germany). Samples were then centrifuged at 16,000 g for 5 min to pellet precipitated 90 
proteins, and supernatant was transferred to a new 2 ml Eppendorf tube. HCl (≥ 32%; Sigma-91 
Aldrich) was added and lipids were hydrolyzed for 16 h at 65°C, then neutralized with 10 M 92 
KOH. Free sphingoid bases were extracted by adding chloroform (99.8%; Sigma-Aldrich) in 93 
basic conditions that contained 2N ammoniac (Sigma-Aldrich). Sphingoid bases were 94 
analyzed by using TSQ Quantum Ultra and Q Exactive liquid chromatography-mass 95 
spectrometry as previously described (6,7). 96 
 97 
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SUPPLEMENTARY FIGURE LEGENDS 122 
 123 
Supplementary Figure 1: Ormdl3-LacZ reportermice as a useful tool to study ORMDL3 124 
expression 125 
A) Western blot showing β-galactosidase expression in different tissues from an Ormdl3-126 
LacZ reporter mouse. For each tissue, 50 ug of protein (determined by Bradford assay) was 127 
loaded. β-tubulin was used as a loading control.  128 
B) Heat map showing Ormdl3 mRNA expression in different murine tissues. The heatmap 129 
demonstrates publicly available RNA-seq data from the Genevestigator database.  130 
C) Western blot showing β-galactosidase expression in lung tissue from PBS-sensitized (non-131 
asthmatic) mice and HDM-sensitized (asthmatic) Ormdl3-LacZ reporter mice. β-tubulin was 132 
used as a loading control. 133 
 134 
Supplementary Figure 2: Effect of altered ORMDL3 expression on sphingolipid 135 
concentration 136 
A) Schematic overview of sphingolipid synthesis. De novo sphingolipid synthesis starts with 137 
the action of serine palmitoyl transferase (SPT), which mediates the condensation of serine 138 
 6 
and palmitoyl-CoA into long-chain bases such as sphinganine. Sphinganines are subsequently 139 
acylated to form (dihydro)ceramides by the action of ceramide synthases (CERS). In the 140 
Golgi, ceramides can be converted to more complex sphingolipids such as sphingomyelin, or 141 
can be broken down by ceramidases to form sphingosine. Sphingosine-1-phosphate (S1P), the 142 
phosphorylated form of sphingosine, is the substrate of S1P-lysase (SGPL), which is the only 143 
enzyme converting sphingolipids into non-sphingolipid molecules. KDSR = 3-144 
ketodihydrosphingosine reductase; DEGS = sphingolipid delta(4)-desaturase; SPHK = 145 
sphingosine kinase; SA1P = sphinganine-1-phosphate; SGPP = sphingosine-1-phosphate 146 
phosphatase 1. 147 
B-P) Ceramide, hexosylceramide, and sphingomyelin levels in different tissues from (non)-148 
asthmatic Ormdl3wt/wt and Ormdl3Tg/wt mice (upper part) and Ormdl3+/+ and Ormdl3-/- mice 149 
(lower part). B-D: lung; E-G: serum; H-J: liver; K-M: brown adipose tissue (BAT); N-P: 150 
white adipose tissue (WAT). 151 
Data information: All data were analyzed with a Shapiro-Wilk normality test to assess 152 
whether the data was normally distributed. Parametric data were analyzed with an ordinary 153 
one-way ANOVA test with multiple comparison correction. Non-parametric data were 154 
analyzed with an unpaired Kruskal-Wallis test with multiple correction. Data are shown as 155 
means +/- SEM. *p<0.05; **p<0.01, ***p<0.001; ****<0.0001. Upper panels (Ormdl3wt/wt 156 
and Ormdl3Tg/wt mice): n=8,13,6,10; lower panels (Ormdl3+/+ and Ormdl3-/- mice): n=5,5,7,7.  157 
 158 
Supplementary Figure 3: ORMDL3 overexpression does not affect allergic asthma 159 
driven by acute or chronic HDM exposures 160 
A) Number of inflammatory cells in bronchoalveolar lavage (BAL) fluid from mock- and 161 
HDM-sensitized Ormdl3wt/wt and Ormdl3Tg/wt mice (n=5,11,7,15).  162 
B) Protein levels of IL-10 and IL-17A secreted by mediastinal lymph node cells during 163 
restimulation with HDM for three days (n=5,11,7,15).  164 
A/B) Data were pooled from 2 independent experiments. 165 
C) Scheme representing the chronic HDM-dependent asthma model. 166 
D) Ormdl mRNA expression levels in lung tissue from PBS and HDM-treated Ormdl3wt/wt 167 
and Ormdl3Tg/wt mice. Expression values were calculated by using qBase+ and were 168 
normalized to reference genes Hmbs and Hprt. Expression values are shown relative to means 169 
of the PBS-treated Ormdl3wt/wt group (n=5,8,5,7). 170 
E) Number of inflammatory cells in BAL fluid from PBS and HDM-treated Ormdl3wt/wt and 171 
Ormdl3Tg/wt mice (n=5,8,5,8). 172 
 7 
F) Protein levels of IL-5 and IL-13 secreted by mediastinal lymph node cells during 173 
restimulation with HDM for three days (n=5,8,5,8).  174 
G) Serum HDM-specific immunoglobulin G1 (IgG1) and HDM-IgE as measured by ELISA 175 
(n=5,8,5,8).  176 
Data information: All data were analyzed with a Shapiro-Wilk normality test to assess 177 
whether the data was normally distributed. Parametric data were analyzed with an ordinary 178 
one-way ANOVA test with multiple comparison correction. Non-parametric data were 179 
analyzed with an unpaired Kruskal-Wallis test with multiple correction. Data are shown as 180 
means +/- SEM. *p<0.05; **p<0.01, ***p<0.001; ****<0.0001. 181 
 182 
Supplementary Figure 4: ORMDL3 does not affect T cell function intrinsically 183 
A) Scheme representing the adoptive transfer of Ormdl3wt/wt and Ormdl3Tg/wt 1-DER T cells 184 
into CD45.1 B6 acceptor mice, which were consequently exposed to HDM.  185 
B) Proliferation profile of adoptively transferred 1-DER T cells labelled with CTV 3 days 186 
after transfer. 187 
C) Proliferation and number of adoptively transferred 1-DER T cells 3 days after transfer 188 
(n=7,7). 189 
 190 
Supplementary Figure 5: ORMDL3 overexpression does not affect allergic asthma 191 
driven by Alternaria alternata 192 
A) Scheme representing the A. alternata-dependent asthma model. 193 
B) Ormdl mRNA expression levels in lung tissue from Ormdl3wt/wt and Ormdl3Tg/wt mice 194 
exposed to either PBS or A. alternata. Expression values were calculated by using qBase+ 195 
and were normalized to reference genes Hprt and Sdha. Expression values are shown relative 196 
to means of the PBS-treated Ormdl3wt/wt group (n=1,7,1,4).  197 
C) Western blot showing β-galactosidase expression in lung tissue from non-asthmatic (PBS-198 
treated) and asthmatic (A. alternata-treated) Ormdl3-LacZ reportermice. β-tubulin was used 199 
as a loading control. 200 
D) Number of B and T lymphocytes in BAL fluid from Ormdl3wt/wt and Ormdl3Tg/wt mice 201 
treated with PBS or A. alternata (n=3,24,3,22).  202 
E) Serum A. alternata-specific IgG1 (OD value) as measured by ELISA (n=1,8,1,9).  203 
F) Protein levels of IL-5, IL-13 and IL-10 secreted by mediastinal lymph node cells during 204 
restimulation with A. alternata for three days (n=3,24,3,22).  205 
D/F) Data were pooled from 3 independent experiments. 206 
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Data information: All data were analyzed with a Shapiro-Wilk normality test to assess 207 
whether the data was normally distributed. Parametric data were analyzed with an ordinary 208 
one-way ANOVA test with multiple comparison correction. Non-parametric data were 209 
analyzed with an unpaired Kruskal-Wallis test with multiple correction. Data are shown as 210 
means +/- SEM. *p<0.05; **p<0.01, ***p<0.001; ****<0.0001. 211 
 212 
Supplementary Figure 6: Loss of Ormdl3 expression does not affect allergic asthma 213 
driven by HDM or Alternaria alternata 214 
A) Number of inflammatory cells in BAL fluid from mock- and HDM-sensitized Ormdl3+/+ 215 
and Ormdl3-/- mice (n=10,11,7,14).  216 
B) Number of neutrophils in BAL fluid and protein levels of IL-17A secreted by mediastinal 217 
lymph node cells during restimulation with HDM for three days (n=10,11,7,14).  218 
C) Ormdl mRNA expression levels in lung tissue from Ormdl3+/+ and Ormdl3-/- mice exposed 219 
to either PBS or A. alternata. Expression values were calculated by using qBase+ and were 220 
normalized to reference genes Hprt and Rpl13a. Expression values are shown relative to 221 
means of the PBS-treated Ormdl3+/+ group (n=4,5,4,6).  222 
D) Number of B and T lymphocytes in BAL fluid from Ormdl3+/+ and Ormdl3-/- mice treated 223 
with PBS or A. alternata (n=6,23,2,22). Data were pooled from 3 independent experiments. 224 
E) Protein levels of IL-5, IL-13 and IL-10 secreted by mediastinal lymph node cells during 225 
restimulation with A. alternata for three days (n=4,14,4,13).  226 
F) Serum A. alternata-specific IgG1 (OD value) as measured by ELISA (n=4,6,4,6).  227 
A/B/E) Data were pooled from 2 independent experiments. 228 
Data information: All data were analyzed with a Shapiro-Wilk normality test to assess 229 
whether the data was normally distributed. Parametric data were analyzed with an ordinary 230 
one-way ANOVA test with multiple comparison correction. Non-parametric data were 231 
analyzed with an unpaired Kruskal-Wallis test with multiple correction. Data are shown as 232 
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